Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (December 2024)
22 slides from Infusystems's investor presentation, Dec 4, 2024
Slide 1: Investor Presentation December 4, 2024
Investor Presentation December 4, 2024 l (NYSE American: INFU) Helping People Live Longer and Healthier Lives
Slide 2: Forward-Looking Statements / Non-GAAP Measures
Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
Slide 3: Five Consecutive Years of Record Revenue
Five Consecutive Years of Record Revenue • Revenue CAGR: 12% • Adjusted EBITDA CAGR: 5% 3 $81.1 $97.4 $102.4 $109.9 $125.8 2019 2020 2021 2022 2023 $20.0 $40.0 $60.0 $80.0 $100.0 $120.0 $140.0 Net Revenues In M ill io ns Investment Highlights 38-Year History | Long-Term Blue Chip Customer Base 2023
Slide 4: Business Highlights
*Source: Newsweek, World's Best Hospitals 2024 4 Business Highlights A leading provider of medical equipment and patient services powered by a 100K+ device fleet in the U.S. and Canada Nearly four decades of experience, built on existing Oncology therapy model and now rapidly expanding into multiple
Slide 5: Providing Solutions To Manage the Device Throughout the Treatment Cycle
5 Providing Solutions To Manage the Device Throughout the Treatment Cycle Device-Agnostic Services Platform That Improves Health Care Processes and Outcomes Patient • SAFE quality equipment • Home treatment • Last-mile solution • 24-hour patient support • Patient satisfaction surveys Manufacturer •
Slide 6: Sales by Segment
SALES BY SEGMENT Total 2023 Revenue: $125.8 Million $49.3M (39%)$76.5M (61%) Device Solutions Providing equipment, products and services to hospitals, clinics and home infusion providers Patient Services Facilitating outpatient care for patients requiring durable medical equipment Patient Services •
Slide 7: Patient Services and Device Solutions Competitive Advantages
Patient Services • 800+ national payer contracts covering over 96% of U.S. population • Focused and scalable revenue cycle management team • 24/7 clinical hotline • Device agnostic Device Solutions • White Glove Concierge approach • 7 facilities serving U.S. and Canada • More than 200 biomedical tec
Slide 8: Patient Services: Oncology Core Business
“The patient is at the center of everything we do.” Patient Services Oncology (Core Business) Is Profitable and Stable Growth Opportunities Are Pain Management and Wound Care Clinical Support/ Case Management Device Logistics Revenue Cycle Management Device Repair & Maintenance 8 Unique High-Service
Slide 9: Device Solutions: Traditional Medical Distribution, Direct Payer Model
Medical Device Sales, Rentals & Leasing Consumable Sales Device Repair & Maintenance Device Solutions Traditional Medical Distribution, Direct Payer Model INFU Is Paid Directly by the Hospital/Clinic/Home Care Provider Trusted Device & Service Provider Inventory & Tracking • Device Solutions (Core B
Slide 10: Managing the Device Throughout the Treatment Cycle
Managing the Device Throughout the Treatment Cycle SOLUTIONS Manufacturer Provider Payer Patient • Distribution • Device support • Improved outcomes • Lower costs • Devices on demand • White Glove services • Third-party payer billing • Access to advanced devices and products • 24/7 patient support C
Slide 11: High-Value Health Care Services Platform
High-Value Health Care Services Platform Specialized Skills We Developed for Oncology Now Being Leveraged in New Therapies and Partnerships 11
Slide 12: InfuSystem's Unique Capabilities Are in High Demand
InfuSystem's Unique Capabilities Are in High Demand February 2021 Acquired and Integrated Two Biomedical Services Companies to Develop and Expand Device Solutions in Acute Care February 2022 Signed Agreement With Solo-Dex Inc. for Proprietary Continuous Peripheral Nerve Block Catheters April 2022 Bi
Slide 13: Quarterly Trends
Quarterly Trends (1) See Appendix A. 13 Net Revenue Quarterly Trend $21.6 $26.0 $25.1 $24.7$24.5 $24.8 $26.6 $26.5$26.8 $27.0 $27.3 $28.8 $30.4 $31.7 $31.9 $31.8$32.0 $33.7 $35.3 2020 2021 2022 2023 2024 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter $— $10.0 $20.0 $30.0 $40.0 Adjusted EBITDA Quart
Slide 14: Annual Financial Performance
Annual Financial Performance 14 $ in M ill io ns $ in M ill io ns Net Revenues $81.1 $97.4 $102.4 $109.9 $125.8 $132.8 $134.2 2019 2020 2021 2022 2023 TTM 9/30/24 Estimated 2024 $— $20.0 $40.0 $60.0 $80.0 $100.0 $120.0 $140.0 $160.0 Adjusted EBITDA (1) $18.2 $26.2 $24.0 $20.7 $22.4 $24.0 $26.5 2019
Slide 15: Annual Margin Performance
Annual Margin Performance 15 Gross Margin 56.8% 59.4% 57.2% 55.1% 50.2% 51.9% 2019 2020 2021 2022 2023 TTM 9/30/24 —% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% Adjusted EBITDA Margin (1) 22.5% 26.9% 23.5% 18.9% 17.8% 18.0% 19.7% 2019 2020 2021 2022 2023 TTM 9/30/24 Estimated 2024 —% 5.0% 10.0% 15.0% 20.0%
Slide 16: Capital Expenditures & Revenue Growth – TTM
Capital Expenditures & Revenue Growth – TTM 16 Capital Expenditures, Net - TTM (000's) TTM Growth Rate Q 1- 20 19 Q 2- 20 19 Q 3- 20 19 Q 4- 20 19 Q 1- 20 20 Q 2- 20 20 Q 3- 20 20 Q 4- 20 20 Q 1- 20 21 Q 2- 20 21 Q 3- 20 21 Q 4- 20 21 Q 1- 20 22 Q 2- 20 22 Q 3- 20 22 Q 4- 20 22 Q 1- 20 23 Q 2- 20 23
Slide 17: Balance Sheet Highlights
Balance Sheet Highlights 17 (1) April 26, 2023, amended the 2021 credit agreement to replace LIBOR with Term SOFR as a benchmark interest rate. New expiration date April 26, 2028. $ in Millions As of September 30, 2024 Equity $55.5 Total Long-Term Debt 1 $28.0 Net Leverage Ratio 1.15x Debt/Equity Ra
Slide 18: Capital Allocation Priorities
18 Capital Allocation Priorities Investments to Drive Organic Growth Initiatives • Device Solutions – Biomedical Services • Patient Services – SI Health Care Technologies Share Repurchase – Opportunistic • $20M Stock Repurchase Program Reduce Debt Levels • Ongoing Financial Flexibility • Maintain Le
Slide 19: Corporate Priorities
Corporate Priorities Maintain Solid Core Business in Oncology and Device Solutions Drive Major Growth Initiatives – Biomedical and Wound Care Continuous Process Enhancements to Boost Net Margins; Sustain Optimal CapEx Efficiency Balance Investment/Growth Initiatives With Improving AEBITDA and Cash F
Slide 20: Questions & Answers
(InfuSystem SAFE. SMART. TRUSTED.” Questions & Answers
Slide 21: Appendix A GAAP to Non-GAAP Reconciliation
Appendix A GAAP to NON-GAAP Reconciliation 21 NET INCOME TO ADJUSTED EBITDA: Twelve Months Ended December 31, Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2020 2021 2022 2023 2023 2024 2023 2024 GAAP net income (loss) $ 17,332 $ 1,420 $ 18 $ 872 $ 689 $ 1,807 $ 800
Slide 22: Executive Team
Barry Steele Executive Vice President & Chief Financial Officer Joined InfuSystem: 2020 Richard DiIorio Chief Executive Officer & Director Joined InfuSystem: 2004 Carrie Lachance President & Chief Operating Officer Joined InfuSystem: 2010 Addam Chupa Executive Vice President & Chief Information Offi
InfuSystem Holdings — Investor Presentation (December 2024) on 6ix